SCHEMBL16936765

SCHEMBL16936765

COc1ccc(Cn2nnnc2-c2c(Br)cc(Cl)cc2S(N)(=O)=O)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 1/20 0.42
ALDH1A1 P00352 7/20 0.40
PKM P14618 1/20 0.40
HTT P42858 3/20 0.39
ERCC5 P28715 1/20 0.39
FEN1 P39748 1/20 0.39
TOP2A P11388 1/20 0.38
ACLY P53396 1/20 0.38
KMT2A Q03164 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
ALOX15 P16050 2/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
HSD17B3 P37058 1/20 0.37
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16936621 0.87 ALDH1A1 (0.39) PTGS2ALDH1A1PKMHTTERCC5
SCHEMBL16936260 0.86 PTGS2 (0.43) PTGS2ALDH1A1PKMHTTERCC5
SCHEMBL16936505 0.85 PTGS2 (0.43) PTGS2ALDH1A1PKMHTTERCC5
SCHEMBL16936530 0.80 NPC1 (0.49) PTGS2L3MBTL1
SCHEMBL16936754 0.80 PTGS2 (0.43) PTGS2ALDH1A1PKMHTTERCC5
SCHEMBL16936686 0.79 PTGS2 (0.42) PTGS2ALDH1A1PKMHTTERCC5
SCHEMBL18234232 0.78 PTGS2 (0.46) PTGS2ERCC5FEN1
SCHEMBL16936349 0.77 PTGS2 (0.41) PTGS2ALDH1A1PKMHTTERCC5
SCHEMBL16936767 0.77 L3MBTL1 (0.48) PTGS2ALDH1A1PKMERCC5FEN1
SCHEMBL16936782 0.77 P2RX7 (0.40) ALDH1A1PKMCA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3096754-B1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME (US) 2018-08-29 EP disclosed
US-9708336-B2 Metallo-beta-lactamase inhibitors MERCK SHARP & DOHME CORP. (US) 2017-07-18 US disclosed
EP-3096754-A1 METALLO-BETA-LACTAMASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-11-30 EP disclosed
US-20160333021-A1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-11-17 US disclosed
WO-2015112441-A1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-07-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160333021-A1 METALLO-BETA-LACTAMASE INHIBITORS MGAM, MGAM2, GAA PTGS2 1698/4885ALDH1A1 329/4885PKM 2536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.